See more : Odyssey Marine Exploration, Inc. (OMEX) Income Statement Analysis – Financial Results
Complete financial analysis of MedX Health Corp (MDXHF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MedX Health Corp, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Axis Corporation (6292.TWO) Income Statement Analysis – Financial Results
- Xinlun New Materials Co., Ltd. (002341.SZ) Income Statement Analysis – Financial Results
- SALA Corporation (2734.T) Income Statement Analysis – Financial Results
- Eledon Pharmaceuticals, Inc. (ELDN) Income Statement Analysis – Financial Results
- China Boton Group Company Limited (3318.HK) Income Statement Analysis – Financial Results
MedX Health Corp (MDXHF)
About MedX Health Corp
MedX Health Corp, a medical device and software company, develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in Canada, the United States, and internationally. The company offers SIAscopy, a medical device technology used to scan skin for suspicious moles and lesions; phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market; and SIAMETRICS, SIMSYS, and MoleMate, which creates real-time images for physicians and dermatologists to evaluate various types of moles or lesions within seconds. It operates DermSecure telemedicine platform that enables the web-based operation of its SIAscopy scanning technology and allows the company to deploy its technology in networks of third-party locations from which patients' mole and lesion images along with other relevant patient information can be connected to specialist physicians for remote assessment. The company was incorporated in 1999 and is headquartered in Mississauga, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 456.09K | 510.61K | 563.10K | 530.07K | 860.25K | 1.09M | 1.09M | 817.06K | 1.17M | 877.73K | 579.65K | 728.29K | 872.58K | 657.36K | 451.38K | 1.15M | 1.06M | 2.60M | 2.93M | 2.74M | 1.32M |
| Cost of Revenue | 270.46K | 270.66K | 273.67K | 261.96K | 380.43K | 398.24K | 478.75K | 379.23K | 509.79K | 390.72K | 269.80K | 299.58K | 381.84K | 244.47K | 689.00K | 315.08K | 371.52K | 571.82K | 656.17K | 503.11K | 211.66K |
| Gross Profit | 185.63K | 239.95K | 289.44K | 268.11K | 479.82K | 689.19K | 614.49K | 437.83K | 661.63K | 487.02K | 309.85K | 428.71K | 490.74K | 412.89K | -237.63K | 834.39K | 684.27K | 2.02M | 2.28M | 2.24M | 1.11M |
| Gross Profit Ratio | 40.70% | 46.99% | 51.40% | 50.58% | 55.78% | 63.38% | 56.21% | 53.59% | 56.48% | 55.49% | 53.45% | 58.87% | 56.24% | 62.81% | -52.65% | 72.59% | 64.81% | 77.98% | 77.62% | 81.65% | 83.97% |
| Research & Development | 586.08K | 681.80K | 995.36K | 431.16K | 535.46K | 880.77K | 182.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 121.79K | 286.50K | 138.75K | 16.80K | 22.41K | 105.18K | 164.58K |
| General & Administrative | 1.66M | 1.80M | 2.08M | 2.79M | 2.94M | 3.80M | 1.83M | 1.56M | 1.30M | 1.00M | 1.20M | 1.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 554.56K | 1.15M | 1.47M | 585.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.21M | 2.94M | 3.55M | 2.79M | 2.94M | 3.80M | 1.83M | 1.56M | 1.30M | 1.00M | 1.20M | 1.71M | 1.28M | 1.30M | 2.29M | 3.18M | 2.62M | 3.00M | 3.69M | 2.23M | 1.32M |
| Other Expenses | -2.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 185.63K | 4.11M | 4.85M | 3.30M | 3.61M | 4.77M | 2.11M | 1.66M | 1.34M | 1.04M | 1.23M | 1.75M | 1.34M | 1.41M | 2.32M | 3.52M | 2.80M | 3.41M | 4.03M | 2.56M | 2.04M |
| Cost & Expenses | 3.48M | 4.38M | 5.13M | 3.56M | 3.99M | 5.17M | 2.59M | 2.04M | 1.85M | 1.43M | 1.50M | 2.05M | 1.73M | 1.65M | 3.00M | 3.83M | 3.17M | 3.99M | 4.68M | 3.07M | 2.25M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.15M | 1.27M | 777.61K | 58.17K | 125.03K | 101.89K | 115.62K | 66.82K | 28.08K | 10.36K | 113.05K | 162.10K | 111.14K | 0.00 | 907.00 | 74.21K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 51.83K | 51.69K | 51.81K | 79.45K | 136.25K | 100.82K | 101.59K | 104.86K | 44.22K | 40.58K | 37.45K | 42.29K | 68.33K | 26.93K | 33.75K | 44.19K | 441.85K | 157.85K | 145.03K | 123.19K | 86.52K |
| EBITDA | -2.38M | -3.82M | -4.54M | -2.95M | -3.02M | -3.98M | -1.39M | -1.16M | -637.39K | -514.97K | -885.43K | -1.28M | -688.63K | -965.65K | -2.52M | -2.64M | -1.67M | -1.23M | -1.60M | -202.55K | -847.27K |
| EBITDA Ratio | -521.55% | -747.48% | -801.09% | -556.53% | -348.06% | -366.37% | -127.38% | -136.50% | -54.41% | -58.67% | -152.75% | -175.71% | -89.97% | -146.90% | -558.13% | -229.78% | -158.55% | -41.23% | -54.73% | -7.39% | -64.19% |
| Operating Income | -3.03M | -3.87M | -4.56M | -3.03M | -3.13M | -4.08M | -1.49M | -1.22M | -681.61K | -555.55K | -922.89K | -1.32M | -853.36K | -992.57K | -2.55M | -2.69M | -2.12M | -1.23M | -1.75M | -325.73K | -933.79K |
| Operating Income Ratio | -663.25% | -757.61% | -810.29% | -571.52% | -363.90% | -375.64% | -136.67% | -149.33% | -58.19% | -63.29% | -159.22% | -181.51% | -97.80% | -150.99% | -565.60% | -233.62% | -200.40% | -47.31% | -59.67% | -11.88% | -70.74% |
| Total Other Income/Expenses | -1.56M | -1.27M | -760.79K | -170.06K | -145.91K | -101.79K | -110.27K | -115.14K | 182.36K | 350.97K | -969.46K | 782.72K | -185.27K | 0.00 | 0.00 | 0.00 | 24.67K | -161.52K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -4.58M | -5.13M | -5.32M | -3.20M | -3.28M | -4.19M | -1.60M | -1.34M | -499.25K | -204.58K | -1.89M | -539.22K | -868.09K | 0.00 | 0.00 | 0.00 | -2.09M | -1.39M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -1,004.31% | -1,005.41% | -945.40% | -603.60% | -380.86% | -385.00% | -146.76% | -163.43% | -42.62% | -23.31% | -326.47% | -74.04% | -99.48% | 0.00% | 0.00% | 0.00% | -198.07% | -53.53% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.27M | 777.61K | 58.17K | 125.03K | 101.89K | 115.62K | 66.82K | 28.08K | 10.36K | 113.05K | 162.10K | 0.00 | 0.00 | 6.01K | 81.32K | 38.46K | 169.01K | 18.60K | 74.92K | 509.05K |
| Net Income | -4.58M | -5.13M | -5.32M | -3.20M | -3.28M | -4.19M | -1.60M | -1.34M | -499.25K | -204.58K | -1.89M | -539.22K | -868.09K | -992.57K | -2.56M | -2.77M | -2.10M | -1.56M | -1.77M | -400.66K | -1.44M |
| Net Income Ratio | -1,004.31% | -1,005.41% | -945.40% | -603.60% | -380.86% | -385.00% | -146.76% | -163.43% | -42.62% | -23.31% | -326.47% | -74.04% | -99.48% | -150.99% | -566.94% | -240.69% | -198.53% | -60.04% | -60.31% | -14.61% | -109.31% |
| EPS | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 | -0.02 | -0.02 | -0.01 | 0.00 | -0.04 | -0.01 | -0.02 | -0.03 | -0.09 | -0.11 | -0.14 | -0.10 | -0.12 | -0.03 | -0.13 |
| EPS Diluted | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 | -0.02 | -0.02 | -0.01 | 0.00 | -0.04 | -0.01 | -0.02 | -0.03 | -0.09 | -0.11 | -0.14 | -0.10 | -0.12 | -0.03 | -0.13 |
| Weighted Avg Shares Out | 196.71M | 183.74M | 180.18M | 166.56M | 140.19M | 130.35M | 103.75M | 83.63M | 70.71M | 67.40M | 42.76M | 36.51M | 34.98M | 30.27M | 27.02M | 24.10M | 15.06M | 15.04M | 14.63M | 12.12M | 10.80M |
| Weighted Avg Shares Out (Dil) | 196.71M | 183.74M | 180.18M | 166.56M | 140.19M | 130.35M | 103.75M | 83.63M | 70.71M | 67.40M | 42.76M | 36.51M | 34.98M | 30.27M | 27.02M | 24.10M | 15.06M | 15.04M | 14.63M | 12.12M | 10.80M |
MedX Health generates revenue in 2Q and expects ‘increasing activity' during the year
MedX Health Corp, the emerging global teledermatology leader, has started to generate revenue from its cloud-based telemedicine platform and patient management system and expects “increasing activity” during the rest of the year. The Mississauga, Ontario-based medical device and software...
MedX Health Corp. Announces Second Quarter 2021 Results
MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (TSX-V:MDX) announced its results for the three and six-months ended June 30, 2021, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $146,532 for the three-months ended June...
MedX Health appoints industry veteran Sylvain Desjeans to its board and names Ken McKay as chairman
MedX Health Corporation has announced the appointment of Sylvain Desjeans to the company's board of directors to fill the vacancy created by the retirement of former chairman Rob von der Porten. Current director Ken McKay has been chosen to replace...
MedX Health announces appointment of Sylvain Desjeans as its president and chief executive officer with immediate effect
MedX Health Corporation has announced the appointment of Sylvain Desjeans as the company's president and chief executive officer with immediate effect. With more than 30 years of healthcare and pharmaceutical industry experience, Desjeans has served in successively senior roles at organizations such...
MedX Health strikes North American distribution deal with VidaCeuticals Health Products
MedX Health Corporation (CVE:MDX) has announced a distribution agreement with VidaCeuticals Health Products Inc to improve accessibility to potentially life-saving scans for skin cancer. The Mississauga, Ontario-based company offers a telemedicine platform, utilizing its SIAscopy technology.
MedX Health Corp. and VidaCeuticals Health Products Inc. Announce North American Distribution Partnership
MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corporation (“MedX” or the “Company”) (TSX-V: MDX) a global leader in teledermatology, is pleased to announce a distribution agreement with VidaCeuticals Health Products Inc. that will see MedX's integrated skin assessment teledermatology platform offered at four...
MedX Health says it has closed two private placements worth a combined $1.5M
MedX Health Corp (CVE:MDX) has announced the closure of an agreement to redeem an existing $500,000 secured loan through a non-brokered private placement of 10 convertible debenture loan notes, each valued at $50,000. The $50,000 notes will be held by...
MedX Health reports 1Q revenue increase year-over-year on higher sales of SIAscope device and telemedicine platform DermSecure
MedX Health Corp (CVE:MDX) has announced an increase in first-quarter revenue year-over-year due to higher sales of its SIAscope image-capture technology and corresponding cloud-based telemedicine platform DermSecure. For the three months ended March 31, the Canada-based company reported revenue of $109,657, versus...
MedX Health Corp. Announces First Quarter 2021 Results
MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the three-months ended March 31, 2021, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $109,657 for the three-months ended March 31,...
MedX Health set to bring in up to C$2.5 million; closes first tranche for c$1,006,600
MedX Health Corporation (CVE:MDX) (OTCMKTS:MDXHF) (FRA:9MH) is poised to raise up to C$2.5 million from a private placing. The medical device and software company will place, with accredited investors, up to around 13.8 million shares at C$0.18 a unit.
Source: https://incomestatements.info
Category: Stock Reports